Centogene (NASDAQ:CNTG) released its quarterly earnings results on Wednesday. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.16), Bloomberg Earnings reports. Centogene updated its FY 2020
Pre-Market guidance to EPS.
Shares of CNTG stock opened at $9.36 on Friday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.79 and a current ratio of 1.98. The firm has a market cap of $185.90 million and a price-to-earnings ratio of -6.41. Centogene has a 52 week low of $7.80 and a 52 week high of $28.71. The firm’s 50-day simple moving average is $11.62 and its two-hundred day simple moving average is $16.31.
Separately, Zacks Investment Research upgraded Centogene from a “sell” rating to a “hold” rating in a research note on Monday, August 17th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Centogene has an average rating of “Buy” and a consensus price target of $20.00.
Centogene B.V. operates as a commercial-stage rare disease company worldwide. It focuses on transforming clinical and genetic data into medical solutions for patients, physicians, and pharmaceutical companies. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs.
Further Reading: History of the Euro STOXX 50 Index
Receive News & Ratings for Centogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centogene and related companies with MarketBeat.com's FREE daily email newsletter.